title: [Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases].
abstract: OBJECTIVE
  Symptomatic lactic acidosis requiring intensive care is a rare and severe adverse event related to the mitochondrial toxicity of the nucleoside analog reverse transcriptase inhibitors (NRTIs).
  
  
  METHODS
  We retrospectively investigated the clinical and biological features of HIV-infected patients who developed severe lactic acidosis syndrome at the University teaching hospital of Bordeaux and the regional community hospital, during 1996-2000.
  
  
  RESULTS
  Nine patients were identified (incidence: 0,9/1000 NRTI treated patient-years), 4 men and 5 women with a median age of 36 years. They had a moderate immunodeficiency (median CD4+ T lymphocyte counts: 197/mm(3)) and only one of them presented a virological failure. The causes of hospital admission were abdominal pain (n = 6), dyspnea (n = 6), asthenia (n = 5), jaundice (n = 4), and vomiting (n = 2). Hepatomegaly was present in 6 patients. Lactic acidosis was found in all cases: median pH: 7.28, bicarbonate: 12 mmol/l, anion gap: 27 mEq/l, plasma lactic acid: 13 mmol/l. Cytolysis (n = 8), cholestasis (n = 6), hepatic failure (n = 4), rhabdomyolysis (n = 4) and pancreatitis (n = 2), were also present. Despite medical intensive care, seven patients died. The only two post-mortem examinations revealed severe hepatic steatosis. Median duration of NRTI therapy was 4 years. At presentation, five patients were receiving lamivudine, five didanosine, four stavudine and three zidovudine. Six patients were coinfected by HCV and/or HBV, four had chronic renal failure and five an immediately preceding infectious disease.
  
  
  CONCLUSIONS
  The prognosis of lactic acidosis is severe. Nucleosid-analog therapy needs clinical and biological monitoring, specially in patients with comorbidities.
authors.affiliation: Fédération de médecine interne, maladies infectieuses et pathologies tropicales, hôpital Saint-André, Bordeaux, France.
authors.forename: F
authors.initials: F
authors.lastname: Bonnet
authors.forename: M
authors.initials: M
authors.lastname: Bonarek
authors.forename: A
authors.initials: A
authors.lastname: Abridj
authors.forename: P
authors.initials: P
authors.lastname: Mercié
authors.forename: M
authors.initials: M
authors.lastname: Dupon
authors.forename: M-C
authors.initials: MC
authors.lastname: Gemain
authors.forename: D
authors.initials: D
authors.lastname: Malvy
authors.forename: N
authors.initials: N
authors.lastname: Bernard
authors.forename: J-L
authors.initials: JL
authors.lastname: Pellegrin
authors.forename: P
authors.initials: P
authors.lastname: Morlat
authors.forename: J
authors.initials: J
authors.lastname: Beylot
mesh_terms: D015746:Abdominal Pain / Q000209:etiology; D000140:Acidosis, Lactic / Q000139:chemically induced*; D000328:Adult; D015897:Comorbidity; D003422:Critical Care; D017809:Fatal Outcome; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D018894:Reverse Transcriptase Inhibitors